These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26270625)

  • 21. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
    Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
    Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
    Schultz NH; Lundblad R; Holme PA
    J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
    Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
    Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
    Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
    J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal.
    Brett S; Taylor M; Pamela M; Michael G
    Clin Appl Thromb Hemost; 2024; 30():10760296241243368. PubMed ID: 38710155
    [No Abstract]   [Full Text] [Related]  

  • 29. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraosseous administration of 4-factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban.
    Ratliff P; Nutley K; Schroeder W; Cottingham L
    J Clin Pharm Ther; 2020 Jun; 45(3):577-579. PubMed ID: 31805210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
    Frost C; Nepal S; Wang J; Schuster A; Byon W; Boyd RA; Yu Z; Shenker A; Barrett YC; Mosqueda-Garcia R; Lacreta F
    Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
    King GS; Cottingham LG; Hughes RE; Ratliff PD
    J Clin Pharm Ther; 2018 Dec; 43(6):903-905. PubMed ID: 29885249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
    Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
    Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of NOACs on Thrombin Generation Assay].
    Kawasugi K
    Rinsho Byori; 2014 Oct; 62(10):965-9. PubMed ID: 27526542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.